Prognostic role of p-mTOR expression in cancer tissues and metastatic lymph nodes in pT2b gastric cancer

被引:61
作者
An, Ji Yeong [2 ]
Kim, Kyoung Mee [3 ]
Choi, Min Gew [1 ]
Noh, Jae Hyung [1 ]
Sohn, Tae Sung [1 ]
Bae, Jae Moon [1 ]
Kim, Sung [1 ]
机构
[1] Sungkyunkwan Univ, Dept Surg, Samsung Med Ctr, Sch Med, Seoul 135710, South Korea
[2] Yonsei Univ, Coll Med, Dept Surg, Seoul, South Korea
[3] Sungkyunkwan Univ, Dept Pathol, Samsung Med Ctr, Sch Med, Seoul 135710, South Korea
关键词
gastric cancer; p-mTOR; prognostic marker; surgery; lymph node metastasis; MAMMALIAN TARGET; PHASE-II; TEMSIROLIMUS CCI-779; GROWTH-FACTOR; RAPAMYCIN; INHIBITOR; PATHWAY; ANTIANGIOGENESIS; THERAPY; TUMORS;
D O I
10.1002/ijc.24872
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Despite the great interest in mammalian target of rapamycin (mTOR) as a potential anticancer therapy target, the prognostic role of mTOR in gastric cancer has not been elucidated. In this study, we investigated mTOR expression in gastric cancer tissues and in metastatic lymph nodes and examined its association with clinical outcome. A total of 290 patients with pT2b gastric cancer were enrolled in this study. Patients were divided into 3 groups according to metastatic lymph node status: Group 1 contained 96 patients without lymph node metastasis, Group 2 contained 102 patients with a few (1-2) metastatic lymph nodes and Group 3 contained 92 patients with extensive (>16) lymph node metastasis. Phosphorylated mTOR expression was determined immunohistochemically using tissue microarrays. p-mTOR expression was observed in 36.5% of the gastric cancer tissues in Group 1, 39.2% in Group 2 and 60.9% in Group 3. A significant correlation was found between p-mTOR expression in gastric cancer tissues and in metastatic lymph nodes. The Borrmann type in Group 1, perineural invasion and p-mTOR expression in metastatic lymph nodes in Group 2 and p-mTOR expression in metastatic lymph nodes in Group 3 were found to be independent prognostic factors of disease-free survival. The 5-year disease free survival rate of Group 2 patients was 84.4% in negative p-mTOR and 66.1% in positive p-mTOR expression in metastatic lymph nodes (p = 0.015). The 5-year disease free survival rate of Group 3 patients was 37.3% in negative p-mTOR and 14.9% in positive p-mTOR expression in metastatic lymph nodes (p = 0.037). There was a linear correlation between the rate of tumor recurrence and mTOR expression scores in metastatic lymph nodes. In pT2b gastric cancer, p-mTOR expression in gastric cancer is associated with the extent of lymph node metastasis, and p-mTOR expression in metastatic lymph nodes is correlated with poor disease-free survival. mTOR may harbor significant potential for a prognostic biomarker and therapeutic target for gastric cancer treatment.
引用
收藏
页码:2904 / 2913
页数:10
相关论文
共 14 条
[1]   Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].
Atkins, MB ;
Hidalgo, M ;
Stadler, WM ;
Logan, TF ;
Dutcher, JP ;
Hudes, GR ;
Park, Y ;
Lion, SH ;
Marshall, B ;
Boni, JP ;
Dukart, G ;
Sherman, ML .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918
[2]   Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors [J].
Buck, Elizabeth ;
Eyzaguirre, Alexandra ;
Brown, Eric ;
Petti, Filippo ;
McCormack, Siobhan ;
Haley, John D. ;
Iwata, Kenneth K. ;
Gibson, Neil W. ;
Griffin, Graeme .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (11) :2676-2684
[3]   Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer [J].
Chan, S ;
Scheulen, ME ;
Johnston, S ;
Mross, K ;
Cardoso, F ;
Dittrich, C ;
Eiermann, W ;
Hess, D ;
Morant, R ;
Semiglazov, V ;
Borner, M ;
Salzberg, M ;
Ostapenko, V ;
Illiger, HJ ;
Behringer, D ;
Bardy-Bouxin, N ;
Boni, J ;
Kong, S ;
Cincotta, M ;
Moore, L .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5314-5322
[4]   Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study [J].
Galanis, E ;
Buckner, JC ;
Maurer, MJ ;
Kreisberg, JL ;
Ballman, K ;
Boni, J ;
Peralba, JM ;
Jenkins, RB ;
Dakhil, SR ;
Morton, RF ;
Jaeckle, KA ;
Scheithauer, BW ;
Dancey, J ;
Hidalgo, M ;
Walsh, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5294-5304
[5]   Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor [J].
Guba, M ;
von Breitenbuch, P ;
Steinbauer, M ;
Koehl, G ;
Flegel, S ;
Hornung, M ;
Bruns, CJ ;
Zuelke, C ;
Farkas, S ;
Anthuber, M ;
Jauch, KW ;
Geissler, EK .
NATURE MEDICINE, 2002, 8 (02) :128-135
[6]   Blocking on the CXCR4/mTOR signalling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells [J].
Hashimoto, Isaya ;
Koizumi, Keiichi ;
Tatematsu, Mikiko ;
Minami, Takayuki ;
Cho, Seiji ;
Takeno, Nobuhiro ;
Nakashima, Akitoshi ;
Sakurai, Hiroaki ;
Saito, Shigeru ;
Tsukada, Kazuhiro ;
Saiki, Izuo .
EUROPEAN JOURNAL OF CANCER, 2008, 44 (07) :1022-1029
[7]   A multicenter study on oncologic outcome of laparoscopic gastrectomy for early cancer in Japan [J].
Kitano, Seigo ;
Shiraishi, Norio ;
Uyama, Ichiro ;
Sugihara, Kenichi ;
Tanigawa, Nobuhiko .
ANNALS OF SURGERY, 2007, 245 (01) :68-72
[8]   Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis [J].
Kobayashi, Soichi ;
Kishimoto, Takashi ;
Kamata, Shigeyuki ;
Otsuka, Masayuki ;
Miyazaki, Masaru ;
Ishikura, Hiroshi .
CANCER SCIENCE, 2007, 98 (05) :726-733
[9]   Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model [J].
Lang, Sven A. ;
Gaumann, Andreas ;
Koehl, Gudrun E. ;
Seidel, Ulrike ;
Bataille, Franke ;
Klein, Dagmar ;
Ellis, Lee M. ;
Bolder, Ulrich ;
Hofstaedter, Ferdinand ;
Schlitt, Hans-Juergen ;
Geissler, Edward K. ;
Stoeltzing, Oliver .
INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (08) :1803-1810
[10]   mTOR and P70S6 kinase expression in primary liver neoplasms [J].
Sahin, F ;
Kannangai, R ;
Adegbola, O ;
Wang, JZ ;
Su, G ;
Torbenson, M .
CLINICAL CANCER RESEARCH, 2004, 10 (24) :8421-8425